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Summary An overview is presented of 23 trials of adjuvant chemotherapy in squamous cell carcinoma of the
head and neck. These were reviewed from the point of view of design of the trial, analysis of survival, response
rates, meta-analysis, site of failure, toxicity and cost. The minimal increase in survival that could be detected
ranged from 11 to 51%, with a median of 25%. No trial was big enough to detect the likely increase of
survival, which is 5%. Many trials excluded some eligible patients before randomisation, the proportion being
21% in those series with details. A further 9% of treated patients were excluded from analysis. A response rate
in four induction studies of 47% equated with a 6% increase in cancer mortality. Meta-analysis showed an
insignificant overall improvement in cancer mortality of 0.5%. Induction chemotherapy, synchronous chemo-
therapy and induction/maintenance chemotherapy did not affect cancer mortality whereas synchronous/
maintenance therapy did. Cisplatinum, methotrexate, bleomycin, 5-FU and a variety of other regimens did not
affect the death rate from cancer, but the combination of VBM significantly increased it. Neither single agent
nor combination chemotherapy produced a significant reduction of cancer deaths. The rate of locoregional
failure was significantly lower in the treated arms, whereas the metastatic rate was similar in both arms. Only
three papers gave full details of toxicity with grading: these showed a high toxicity rate. The mortality rate
from chemotherapy in nine series averaged 6.5%.
Adjuvant chemotherapy may be used in three ways in the
treatment of squamous cell carcinoma of the head and neck:
as induction therapy before other forms of treatment, syn-
chronously with radiotherapy, or as maintenance therapy
after radical radiotherapy and/or surgery. Its place has been
reviewed by several authors (Cachin, 1982; Chang, 1988;
Forestiere, 1986; Glick & Taylor, 1981; Hong, 1988; Mead &
Jacobs, 1982; Tannock & Browman, 1986) who have mostly
concluded that adjuvant chemotherapy does not show any
survival benefit compared with conventional surgery or
radiotherapy. However, a review must satisfy certain criteria
before we can accept its findings. In particular, it ought to
encompass all published (and, if possible, unpublished)
reports - otherwise it may be seriously biased. Most of the
above papers review only some of the reported papers. For
example, one review of induction chemotherapy only con-
siders two of the eight published series (Hong, 1988); the
validity of a review which ignores three-quarters of the pub-
lished material must be questioned.
A review should be comprehensive and should cover the
following topics.
Design of the trial: (a) What is the minimal likely increase
in survival, and are the trials reviewed large enough to detect
this minimal likely increase? (b) Were any eligible patients
excluded from analysis? Only Tannock and Browman (1986)
consider these points.
Analysis of the results: The method of survival analysis
may be based on total mortality or cancer mortality, and this
can affect the interpretation of the outcome. It is reasonable
to analyse only deaths due to cancer if adjuvant
chemotherapy does not change the death rate due to other
causes. However, deaths due to toxicity may reduce any
benefit of treatment and the 'swings and roundabouts' inter-
play of improvement in survival compared with deaths due
to toxicity should be analysed.
Survival: A review should analyse the extent and direction
of any change in survival. All the above authors consider
only two outcomes, benefit and no benefit; none considers
the possibility that treatment might worsen survival. In fact,
there are three outcomes to a controlled trial: survival may
be better in the treated arm, it may be worse in the treated
arm, or the outcome may be the same in both groups. The
latter event (demanding that there is exactly the same
number of deaths at exactly the same interval) is so unlikely
that it can be ignored. Thus, there are two outcomes, im-
provement or worsening of survival, and what needs to be
analysed is the direction and magnitude of the difference
between the two arms.
If most of the trials reported show an improvement in
survival in the same direction but none is significant, there
may be an overall significant effect which can be revealed by
a meta-analysis, a technique in which the results of several
trials are pooled. However, if about half the trials show
improvement and the other half of equally sized and equally
reliable trials show the opposite, a meta-analysis is likely to
show that such treatment is ineffective (Peto, 1987). The
mathematical basis of meta-analysis is described in Appendix
2. A nice illustration of this technique has recently been
provided by a meta-analysis of the use of streptokinase in
myocardial infarction. Numerous trials of streptokinase car-
ried out many years ago showed no clear benefit, but a
meta-analysis suggested that this drug probably did improve
survival although no trial large enough to detect its effect had
been mounted. A large multinational trial which admitted
17,187 patients was then carried out. The drug reduced mor-
tality by 3% and this outcome was highly significant. This
drug has been available for use in this context for the past 30
years, and it is estimated that its earlier adoption would have
saved 1,000,000 lives worldwide (Second International Study
of Infarct Survival Collaborative Group, 1988). This trial
illustrates clearly the pitfalls of conclusions drawn from trials
that are too small, and the fact that even a small difference, if
real, can be of substantial benefit.
Site offailure: Only two papers consider the question of
site of failure (Glick & Taylor, 1981; Tannock & Browman,
1986).
Toxicity: All reviews bar two (Hong, 1988; Mead &
Jacobs, 1982) consider toxicity, although none summarises
the death rate from toxicity specifically.
Cost: No review considers the cost of these regimens and
whether they achieve a justifiable cost:benefit ratio.
Material and methods
A review is presented here of all the trials of adjuvant
chemotherapy in squamous carcioma of the head and neck
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published in the English language. Several trials have been
excluded from the analysis for the following reasons: first,
several well designed studies do not report the survival rate
(Bakowski et al., 1978; Fletcher et al., 1963; Kapstad et al.,
1978; Richards & Chambers, 1969; Shanta & Krishnamurthi,
1980); second, one study was not randomised, as the control
arm consisted of those rejected for radical treatment (John-
son et al., 1985); third, one trial did not include an arm
receiving conventional treatment only (SECOG, 1986); fourth
one trial (Shanta & Krishnamurthi, 1980) reported disease-
free survival only, and coud therefore not be analysed for
mortality.
This left 23 randomised controlled trials with survival data
(Arcangeli et al., 1983; Cachin et al., 1977; Ervin et al., 1987;
Fazekas et al., 1980; Fu et al., 1987; Gollin et al., 1972;
Gupta et al., 1987; Head and Neck Contracts Program, 1987;
Holoye et al., 1985; Hussey & Abrams, 1975; Knowlton et
al., 1975; Lo et al., 1976; Martin et al., 1986; Nissenbaum et
al., 1984; Pearlman et al., 1985; Petrovich et al., 1981; Rent-
schler et al., 1987; Schuller et al., 1988; Stefani et al., 1971;
Stefani & Chung, 1980; Stell et al., 1983; Stolwijk et al.,
1983; Taylor et al., 1985; Toohill et al., 1987; Vermund et al.,
1985). The data for dosage, timing of chemotherapy, site
stage and local treatment of the tumour are shown in Tables
I -III. Where the trials have been reported on several
occasions the data for the latest report have been used. The
trial run from Madison, Wisconsin, was reported in its
entirety by Gollin et al. (1972) and a subgroup of patients
with tumours of the oral cavity and oropharynx, with addi-
tional patients, was later reported by Lo et al. (1976). The
data for tumours of the mouth and oropharynx are taken
from the latter paper, and those for other sites from the
former, but the two are otherwise treated as one trial. The
results for the trial first described in 1971 by Stefani were not
reported until 1980 (Stefani & Chung, 1980). Again, these are
treated as one trial.
Design ofthe trial
Power of the trial The minimal difference in survival which
each trial would be likely to detect was calculated from the
formula given by George (1984) (Appendix 1). It is based on
the number of patients in each trial, on the survival rate of
the control arm, and on an assumption of a type 1 error of
5%, and a type II error of 20%, these being commonly
regarded as the minimal acceptable values for these
parameters.
Randomisation The reports were examined for details of
eligible patients excluded before randomisation.
Analysis ofsurvival
Exclusion of treated patients The reports were examined for
details of treated patients excluded from analysis.
Method of calculation of survival The type of survival
analysis (cancer deaths or total mortality) was recorded.
Table I Patients' details: cisplatinum based regimens
Tumour Type of Local
Reference Tumour site stage chemotherapy Treatment Dose
7 M,A,N,O,L III-IV Ind/main Surg/DXRT Cisplatin 20gm-2 d 1-5
Bleomycin i.v. 10 um-2 d 3-7
Methotrexate 200mgm2 d 15,22,29,36
17 M,O,H,L III-IV Ind/main Surg + DXRT Cisplatinum 100gm2 d 1
Bleomycin 15 gm-2 d 3-7
25 M,O Ind DXRT Cisplatinum 120gm-2d4
5-FU600mgm-2d1-5
Bleomycin i.v. 10urM-2 d 2
Methotrexate 120 mg m-2 d 2
29 M,O,N,H,L III-IV Syn/main DXRT Cisplatinum 20mg m-2 i.v. d.
1,2,3
Bleomycin 10 gm-2 dl,3,5,7
30 O,H,U III-IV Ind/main DXRT ± surg Cisplatinum 50 mg m-2i.v. Once before
Methotrexate 30mg/m-2 i.v. and once
Bleomycin 10 u m-2 after DXRT
35 M,O,H,L III-IV IND Surg + DXRT Cisplatinum 50mg m-2 i.v.
MTX 40Mg/in2 i.V.
q1 dy
Bleomycin 15 um-2 i.V. q 21 days
Vincristine 2 mg i.v.
48 M,O,N,A,G,H III-IV IND DXRT/surg Cisplatinum 100 gm-2
5-FU 500gm-' 1-5 days
M, oral cavity; A, nose and sinuses; N, nasopharynx; 0, oropharynx; H, hypopharynx; L, larynx; U, unknown parity.
Table II Patients' details: methotrexate based regimens
Tumour Type of Local
Reference Tumour site stage chemotherapy treatment Dose
I M,O,A II-IV Induction DXRT 3-5 mg i.a. d 1-42
8 M,A,N,O,H,L, III-IV Induction DXRT 25 mg i.v. d3,6,9,12,15
16 M,O,H,N,A III-IV Synchronous DXRT 100mgm2 i.v. d 0 & 14
23 A,M,N,O,H,L,U III-IV Induction DXRT Escalated to 240 mg m-2
d 1-5
32 M,N,O,H IV Induction DXRT 50- 100 mg kg i.v.
Vincristine 0.015 mgkg-' i.v.
33 M,O,H,L III-IV Induction/ Surgery 40 g m-2
maintenance DXRT escalated to 80mg m-2
weekly x 16
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Table III Miscellaneous regimens
Tumour Tumour Type of Local
Reference sitea stage chemotherapy treatment Agent & dose
4 0 II-IV Syn DXRT Bleomycin 15mg i.m. 2 week-'
12 M,N,O,H,L III-IV Syn/main DXRT Bleomycin 5 u i.v. 2 wk-' during DXRT
Bleomycin 15 u i.v. weekly x 16 main
MTX 25 mg m-' i.v. weeky x 16 main
15,24 M,O,N,H,L,U II-IV Syn DXRT 5-FU i.v. 10mg kg-' daily days 1-3
then 5 mgkg-' 3 times weekly
18 M,A,L,H,N,O III-IV Ind/Main DXRT/Surg Bleomycin 10 units/t.d.s. d 1-4
Cyclophos 200 mg m-2 d 1-5
Methotrexate 30 gm-2 d I and 5
5-FU 400mgm2 d 1-5
20 M,O,L,N,A,U I-IV Syn DXRT Hydroxyurea 60 mg kg-' 3 times wkly
40,41 M,O,L,N,A,H Syn DXRT Hydroxyurea 80 mg kg-' twice a week
42 M,L,O,N,H III-IV Ind/main DXRT Vincristine 1.5 mg m-2 i.v. 0 h
Methotrexate 75 g m-2 12 h
Methotrexate 75 g m2 i.v. 15 h
Bleomycin 60 mg i.v. 15 h
Methotrexate 75 gm-2 i.v. 18 h
5-FU 350 mg m-2 i.v. 18 h
Hydroxyurea 3 g m-2 0 h
6MP 150 g m-2 orally 6 h
Cyclophos 500mg m-2 i.v. 12 h
45 L,H,O,M,N,EAR III-IV Ind/main DXRT Vinblastine 6 mg m-2 0 h
Bleomycin 15 mg i.m. 8 h
Methotrexate 40 mg m-2 24 h
Cyclophos 400 mg m-2 24 h
5-FU Smgkg-' 24h
47 M,L,O,N,H III-IV Ind/main DXRT + surg Induction:
methotrexate 60mg/M2 6 hourly
dl,5,9
Maintenance
cisplatinum 40 mg m-2)
adriamycin 40 mg m-2) 3 wks x 4
49 M,O,N,H,L,A II-IV Synch DXRT Bleomycin total dose 100 mg i.v.
aSee Table 1.
Response rates
These apply only to induction trials. The response rates are
summarised where they have been reported, and the survival
in these trials analysed.
Meta-analysis
The appropriate data for survival were extracted from the
papers quoted and were subject to meta-analysis (Peto, 1987).
The mathematical basis of this technique is shown in Appen-
dix 2.
The death rate (number of deaths/total number) used for
these analyses was that up to 2 years where these data were
available. In some reports, information about the outcome of
each patient is provided but, in general, this was not so. In
most of the papers, any losses to follow-up during the first 2
years could not be taken into acount and the quoted death
rates may, therefore, be slightly too low.
This small bias applies equally across treatment groups,
however, and should not affect the significance of the sur-
vival comparison. In those trials in which the number of
deaths by 2 years was not given, the number of deaths
(rounded to the nearest integar) was calculated as (I
-S) x (total number ofpatients), where S is the survival rate
at 2 years estimated from the relevant survival curve. In five
series data were available at only one point in time, and not
at two years. The data used were then the death rate at 1
year (Martin et al., 1986; Stolwijk et al., 1983), 18 months
(Petrovich et al., 1981), 5 years (Stefani & Chung, 1980) and
at the time of writing (Gollin et al., 1972). These problems
mean that the meta-analysis results are not exact. Never-
theless, they are good enough to indicate any trends.
A meta-analysis is provided of the pooled results of all the
trials, together with subgroup analyses for the main groups
of chemotherapy regimens, for the different timing of
administration (induction, synchronous and maintenance),
for various sites and for single agents versus combinations.
The odds ratios with approximate 95% confidence inter-
vals for these different forms of treatment were also cal-
culated using the formulae shown in Appendix 3.
Site offailure
The concept is gaining ground that adjuvant chemotherapy
might be useful in reducing the proportion of patients who
require salvage surgery for failed radiotherapy. Also some
believe that it might increase the rate of distant metastases
(Vermund et al., 1985), and some that it might reduce it
(Schuller et al., 1988). Therefore data for site of failure were
extracted when they were available.
Toxicity
All papers were reviewed for reports of toxicity, in particular
deaths and the use of a grading system as recommended by
the WHO (Miller et al., 1981).
Cost
The cost of induction and maintenance regimens was cal-
culated based on the cost of a bed per day in an English
teaching hospital in 1987, which was £152.78 (Stell, 1987).
The length of stay was that given in each article, plus an
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for recovery from the effects of chemotherapy. The cost of
drugs was ignored as this is relatively small; furthermore the
cost of synchronous chemotherapy was not calculated as it
usually does not require an extra stay in hospital, and its cost
is, therefore, minimal.
Results
Design ofthe trial
Power of the trial The minimal difference in survival which
could be detected by each trial ranged from 11 to 51% with a
median of 25%.
Randomisation All the trials reviewed were randomised, but
many did not describe the randomisation process. Four trials
did not specify whether eligible patients were excluded from
randomisation. Twelve authors described exclusion of eligible
patients before randomisation, but only five authors (Ervin et
al., 1987; Fu et al., 1987; Holoye et al., 1985; Schuller et al.,
1988; Toohill et al., 1987) give details of how many eligible
patients were excluded. These latter five trials contained a
total of 648 patients, 134 (20.7%) of eligible patients were
excluded before randomisation. In four trials there were no
exclusions from randomisation, but some treated patients
were excluded from analysis (v.i.). Only five adhered to the
policy of 'intention to treat' (Gupta et al., 1987; Pearlman et
al., 1985; Stell et al., 1983; Stolwijk et al., 1983; Vermund et
al., 1985), i.e. all eligible patients were randomised and
included in the analysis, whether treated or not.
Analysis ofsurvival
Exclusion of treated patients Nine reports excluded some
treated patients from the final analysis (Cachin et al., 1977;
Fazekas et al., 1980; Fu et al., 1987; Head and Neck Con-
tracts Program, 1987; Hussey & Abrams, 1975; Lo et al.,
1976; Martin et al., 1986; Stefani & Chung, 1980; Taylor et
al., 1985). Out of a total of 2012 patients in these nine trials
183 patients were excluded from the analysis (9.1%).
Method of calculation of survival Eleven authors analysed
cancer deaths alone, three reported total mortality, one did
not state how survival was calculated and seven authors gave
full details of the fate of all patients at a specific interval.
From these latter seven it is possible to calculate the
difference between cancer survival and crude survival
(Holoye et al., 1985; Knowlton et al., 1975; Pearlman et al.,
1985; Petrovich et al., 1981; Taylor et al., 1985; Toohill et al.,
1987; Vermund et al., 1985) (Table IV).
Chemotherapy increased the total mortality by 5.0%
whereas the difference in cancer death rates was 2.4%. Thus,
an analysis restricted to cancer deaths underestimated the
death rate by 2.6%, probably because deaths due to toxicity
were not included in the analysis.
Response rates
Response rates using WHO criteria were only quoted in four
of the induction studies. The results (Table V) show that a
response rate of 46.9% equated with an increase in death
rate of 6.4%, although this change was not significant.
Meta-analysis
A total of 3,683 patients were eligible and of these, 3,398
patients were randomised. The death rate was 885/1,560
(56.7%) in the control arms, and 969/1724 (56.2%) in the
treated arms, an improvement of survival of 0.5% in the
chemotherapy arms. Meta-analysis showed that the sum of
(O - E) over all trials was -4.29 and its variance 201.39.
This difference is not significant (z=-0.30). The odds ratio
was 1.02 and its 95% confidence interval 0.89-1.17.
The subgroup analysis was carried out for the different
agents, irrespective of whether they were used for induciton,
maintenance, etc. (Tables VI to IX). This showed that the
VBM regimen significantly increased the death rate from
cancer, whereas all the other regimens were ineffective.
Subgroup analysis for the timing of chemotherapy
(irrespective of the agents used) is shown in Table X. Induc-
tion chemotherapy, synchronous chemotherapy and
induction/maintenance were completely ineffetive, whereas
synchronous/maintenance therapy significantly reduced
deaths from cancer (P <0.05).
A subgroup analysis for site (irrespective of agents and
timing of use) is given in Table XI. No significant differences
were found.
Finally, subgroup analysis of the number of agents
(irrespective of agent and timing of use) showed that neither
single agents nor multiple agents produced a significant
reduction of the death rate.
Site offailure
Data about the site of failure were given in 10 papers. The
results are summarised in Tables XIII and XIV. The failure
rate from locoregional recurrence was 6.7% less in the
treated groups, and this difference was highly significant
(P<0.01). The failure rate for distant metastases was 2.0%
lower in the treated group, but this was not significant.
Toxicity
Toxicity was reported fully and graded in only three papers
(Ervin et al., 1987; Fu et al., 1987; Schuller et al., 1988). Nine
papers gave details of toxicity, with no grading scheme, eight
papers dismissed it in a few words, e.g. 'mild and transient'
(Arcangeli et al., 1983), and four did not mention it at all.
No paper used the scheme recommended by the WHO
(Miller et al., 1981).
Deaths from toxicity were mentioned in 10 series (Ervin et
Table IV Difference between total and cancer mortality
Control arm Treated arm (O-E) Variance Z P
Total mortality 158/311 172/308 1.26 n.s.
(50.8%) (55.8%) 7.80 38.58
Cancer mortality 157/311 163/308
(50.5%) (52.9%) 3.78 38.70 0.61 n.s.
Table V Response rates and survival
Response Deaths
Reference rate Control arm Treated arm O-E Var Z P
17 104/282 67/152 62/140 0.15 18.03 0.04 n.s.
25 18/28 9/27 14/28 2.29 3.41 1.24 n.s.
32 8/12 10/11 10/12 -0.43 0.68 -0.52 n.s.
35 56/75 34/76 49/82 5.92 9.90 1.88 n.s.
Total 186/397 120/266 135/262 8.47 33.02 1.47 n.s.
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Table VI Meta-analysis: cisplatinum regimens
Deaths
Reference Control arm Chemotherapy arm O-E Variance Z P
7 7/20 3/26 -2.65 1.97 - 1.89 n.s.
17 67/152 Ind 62/140 0.15 18.03 0.04 n.s.
Main 59/151 -3.79 18.46 -0.88 n.s.
25 9/27 14/28 2.29 3.41 1.24 n.s.
29 13/13 15/23 -2.89 1.48 -2.38 <0.025
30 18/28 15/31 -2.34 3.69 1.22 n.s.
35 34/76 49/82 5.92 9.90 1.88 n.s
48 11/33 12/27 1.65 3.57 0.87 n.s.
Total 159/349 229/508 -0.99 51.32 -0.14 n.s.
(45.6%) (45.1%)
Odds ratio 1.02 (0.78-1.34)
Table VII Meta-analysis: methotrexate regimens
Deaths
Reference Control arm Chemotherapy O-E Variance Z P
1 35/70 26/72 -4.93 8.76 - 1.67 n.s.
8 225/326 223/312 3.92 33.79 0.68 n.s.
16 83/157 72/156 -5.25 19.62 - 1.19 n.s.
23 34/48 41/48 3.50 4.14 1.72 n.s.
32 10/11 10/12 -0.43 0.68 -0.52 n.s.
33 10/27 9/28 -0.67 3.17 -0.38 n.s.
Total 397/639 381/628 -4.62 75.12 -0.53 n.s.
(62.1%) (60.7%)
Odds ratio 1.06 (0.85-1.33)
Table VIII Meta-analysis: VBM regimens
Deaths
Control Treated
Reference arm arm (O-E) Variance Z P
42 1839 34/47 5.58 5.16 2.46 <0.025
45 8/35 14/33 3.32 3.77 1.71 n.s.
Total 26/74 48/80 9.56 9.66 3.08 <0.01
(35.1%) (60.0%)
Odds ratio 0.36 (0.19-0.69)
Bleomycin regimens
4 48/87 57/99 1.11 11.45 0.33 n.s.
12 33/51 22/45 -3.78 5.91 -1.55 n.s.
49 40/111 48/111 4.0 13.34 1.10 n.s.
Total 121/249 127/255 1.52 31.55 0.27 n.s.
(48.6%) (49.8%)
Odds ratio 0.95 (0.67- 1.35)
S-FU regimen
15,24 64/79 52/76 -4.88 7.34 - 1.80 n.s.
(81.0%) (68.4%)
Odds ratio 1.97 (0.94-4.13)
Table IX Meta-analysis: miscellaneous regimens
Deaths
Control Chemotherapy
Author arm arm (O-E) Variance Z P
18 23/39 25/38 1.31 4.58 0.61 n.s.
20 11/15 16/23 -0.34 1.92 -0.25 n.s.
40,41 62/75 70/75 4.00 3.99 2.00 <0.05
47 22/41 21/41 -0.50 5.18 -0.22 n.s.
Total 118/170 132/177 4.48 17.51 1.07 n.s.
(69.4%) (74.6%)
Odds ratio 0.77 (0.48-1.24)
al., 1987; Fazekas et al., 1980; Fu et al., 1987; Holoye et al.,
1985; Knowlton et al., 1975; Nissenbaum et al., 1984; Pearl-
man et al., 1985; Schuller et al., 1988; Stell et al., 1983;
Stolwijk et al., 1983). One of these did not record the number
of deaths due to toxicity, but stated that serious complica-
tions, including death, occurred in 'less than 10% of all
patients' (Knowlton et al., 1975). In the remaining nine
reports, the total mortality from chemotherapy was 41/627,
i.e. 6.5%. The death rate in these nine trials totalled 379/627
in the control arm and 400/637 in the treated arm. Thus, in
these nine trials the death rate was 2.4% higher in the treated
arms, to which must be added a further 6.5% increase in
deaths due to toxicity, making a total reduction in survival of
8.9%. Eight of these 10 trials were of induction chemo-
therapy, and two were of synchronous chemotherapy.
Cost
One paper (Pearlman et al., 1985) mentioned the issue of cost
but did not measure it. No other paper mentioned this
aspect. None recorded the number of days in hospital. How-
ever, a very crude calculation based on the number and
length of the courses shows that the median number of days
was 22, with a range of 3-50. Thus, the cost ranged from
£458 to £7,639, the median being £3,361.
Discussion
Given that the overall survival of squamous carcinoma of the
head and neck has not improved in a generation (Stell et al.,
1986) it is very unlikely that a major improvement in survival
is to be expected from manipulations of the various forms of
treatment currently available. Real improvement in survival
of 5% would be very worthwhile and is realistically all that
might be achieved in the present circumstances; a 10% im-
provement is just conceivable, but it is unreasonable to
expect any improvement beyond this with currently available
forms of treatment.
This overview shows that no trial yet mounted is big
enough to detect the probable degree of improvement from
chemotherapy, that is between 5 and 10%. The least
difference which could be reliably detected by these trials was
11%, and the median was 25%. Any new form of treatment
which produces an improvement in survival as great as 25%
would be adopted rapidly, without the necessity for a trial.
Only about a quarter of these trials adhered to the policy
of 'intention to treat', and many excluded some eligible
patients from randomisation. Where details were given, it
emerged that over a third of eligible patients were excluded
before randomisation. Furthermore, 10% of treated patients784 P.M. STELL & N.S.B. RAWSON
Table X Meta-analysis: type of chemotherapy
Reference Sum (O-E) Sum (var) Z P Odds ratio (95% CI)
Induction
1,8,23,25,32 11.63 68.69 1.40 n.s. 0.84 (0.67- 1.07)
35,48
Synchronous
4,15,16,20,24, -1.18 64.60 -0.15 n.s. 1.02 (0.80-1.30)
40,41,49
Induction/maintenance
7,17,18,30,33, 0.39 55.20 -0.05 n.s. 1.01 (0.77-1.31)
42,45,47
Synchronous/maintenance
12,29 -5.76 7.75 -2.07 <0.05 2.14 (1.04-4.42)
Table XI Meta-analysis: site
Reference Sum (O-E) Sum (var) Z P Odds ratio (95% CI)
Mouth
1,8,16, -9.0 21.60 - 1.94 n.s. 1.52 (0.99-2.33)
24
Oropharynx
1,4,8,16 -7.93 42.24 -1.22 n.s. 1.21 (0.89-1.63)
24,32
Larynx & hypopharynx
8,15,16 -3.16 -0.80 n.s. 1.22 (0.75-2.01)
Table XII Meta-analysis: number of agents
Reference Sum (O-E) Sum (var) Z P Odds ratio (95% CI)
Single agent
1,4,8,15,
16,20,
23,24,33,
40,41,49 -0.54 118.20 -0.05 n.s. 1.00 (0.84-1.20)
Multiple agents
7,12,17,18,
25,29,30,32,35,
42,45,47,48 2.27 79.35 0.25 n.s. 0.97 (0.78-1.21)
Table XIII Meta-analysis: locoregional failure
Reference Control arm Treated arm (O-E) Var Z P
1 44/70 32/72 -6.54 8.89 -2.19 <0.05
8 75/173 69/164 - 1.08 20.66 -0.24 n.s.
16 72/156 53/156 -9.50 18.79 -2.19 <0.05
17 36/144 35/135)
31/132) -0.26 17.50 -0.06 n.s.
18 16/39 24/38 4.26 4.87 1.93 n.s.
20 10/16 15/24 0.00 2.31 0.00 n.s.
23 33/48 37/48 +2.00 4.79 0.91 n.s.
24 38/56 27/56 -5.50 6.88 -2.10 <0.05
48 10/33 12/27 2.10 3.51 1.12 n.s.
49 70/111 61/111 -4.5 13.48 -1.22 n.s.
Total 404/846 396/963 -29.87 111.15 -2.83 <0.01
(47.8%) (41.1%)
Odds ratio 1.31 (1.09-1.58).
Table XIV Meta-analysis: distant metastases
Reference Control arm Treated arm (O-E) Var Z P
1 13/70 12/72 -0.68 5.19 -0.30 n.s.
8 27/173 16/164 -4.93 9.40 -1.61 n.s.
17 27/144 26/135) -4.23 12.49 - 1.20 n.s.
12/132)
18 5/39 1/38 -1.96 1.40 -1.66 n.s.
23 11/48 6/48 -2.50 3.53 -1.33 n.s.
24 6/56 5/56 -0.50 2.50 -0.32 n.s.
48 2/33 1/27 -0.35 0.72 -0.41 n.s.
49 13/111 26/111 6.50 8.07 2.29 <0.025
Total 104/674 105/783 -7.32 44.54 -1.10 n.s.
(15.4%) (13.4%)
Odds ratio 1.18 (0.88-1.56).ADJUVANT CHEMOTHERAPY IN HNC 785
were excluded from analysis and this must be an enormous
source of bias because it is highly likely that excluded
patients do badly. A further source of bias of any review of
published trials is the fact that small trials and negative trials
are unlikely to be reported (publication bias). Finally, most
trials did not report the actual mechanism of randomisation,
and it may be that some used systems, such as randomising
by the date of birth, which allow the clinician to know
beforehand the treatment arm to which a patient would be
allocated.
Most of the trials relied on analysis of cancer deaths rather
than total mortality. Although chemotherapy does not affect
the rate of intercurrent deaths, nor the survival of patients
lost to follow-up, calculation should nonetheless be based on
total mortality because deaths from toxicity may be counted
as intercurrent deaths, thus giving a false sense of the overall
picture. The analysis of cancer mortality rather than crude
survival in the series reviewed here inflated the survival rate
of the chemotherapy group by 2.6%, indicating that some
deaths due to toxicity were counted as intercurrent deaths.
The analysis of deaths due to other causes is a serious
problem in trials in which they contribute a substantial pro-
portion of total mortality. However, the risk of death from
other causes is low during the first few years after diagnosis
and, for trials of advanced cancer, the simplest and most
reliable analysis is that based on total mortality.
Meta-analysis showed that, overall, the chemotherapy
arms fared slightly better than the control arms, the
difference in cancer mortality being 0.5%. However, analysis
of the seven trials which gave full details and were, therefore,
the most reliable showed an increase of 5.0% in mortality.
Subgroup analysis suggests that cisplatinum, methotrexate,
bleomycin, 5-FU and miscellaneous regimens were ineffective,
whereas VBM produces a significant reduction in survival.
Subgroup analysis also suggests that synchronous/
maintenance therapy is probably effective (although this
result is based on only two trials), whereas induction,
induction/maintenance and synchronous therapy are not.
Single agents are not better than combinations. Finally,
adjuvant therapy does not benefit tumours of any particular
site.
The available data for site of failure suggest that
chemotherapy reduces the rate of locoregional failure, thus
improving quality of survival. There is no evidence that it
either increases or decreases the distant metastatic rate.
Although many authors dismiss toxicity lightly, it is clear
form the few available data from the death rate of 6.5%
form toxicity that this conclusion is not justified.
The figures for cost are very aproximate and do not in-
clude drug costs. They also relate only to induction and
maintenance regimens, since synchronous regimens usually
do not prolong stay in hospital. It has been shown that the
maximum cost per patient, per year of life saved, that the
UK National Health Service can sustain is£17,000 at 1987
prices (Stell, 1987). Induction or maintenance chemotherapy
would thus need to increase survival by 20-25% to be
affordable. As they increase survival by 5% at most, they are
not affordable.
This review has many sources of bias, some of which have
already been referred to, but the main source of inaccuracy is
the difficulty of extracting complete data from the various
reports. In particular the survival at 2 years often had to be
read off a very small graph; although the number of patients
admitted to the trial was always given, the number at risk at
this or any other time interval was often not given. For some
of the studies an alternative end-point had to be used, e.g. 5
year survival. This was not ideal but the sum of the observed
and expected numbers of deaths from these analyses still
provides a valid and reasonably efficient global test of wheth-
er there is a difference in survival.
Moreover, the subgroup analyses should be treated with
great caution. Subgroup analysis should only be carried out
if the following criteria are satisfied: (a) the analysis was
intended at the start of the trial; (b) the analysis is not liable
to bias; (c) the analysis is biologically plausible; (d) the result
of the trial is significant overall (Bulpitt, 1988). Therefore,
Peto (1987) advises reporting subgroup analyses but treating
them with grave suspicion. However, they may be useful
pointers to further trials.
The authors wish to make a strong plea to both authors
and editors of journals that reports of cancer clinical trials
should include the following:
1. Calculation of sample size and of the minimal difference
likely to be detected by the trial (the power of the study).
2. Details of the fate of eligible patients excluded form ran-
domisation.
3. Details of the fate of treated patients excluded from the
analysis.
4. Both total and cancer mortality.
5. A full table of results at 2 and 5 years.
6. Toxicity, using the WHO scale.
7. Deaths from toxicity.
8. Cost.
Appendix 1
The formula for calculating the minimal number of events
needed to detect a given difference in an individual was
adapted from the following formula given by George (1984).
(Zai2 + Zb)2
2 (arc sin -vr, - arc sin Vr2)2
where r, ='cure' rate in control group; r2='cure' rate in
treated group; Za/2 = normal deviate for type 1 error;
Zb = normal deviate for Type II error; n = number in each
arm.
Appendix 2
The meta-analysis is that described by Peto (1987).
The expected number of deaths in the treated arm is
calculated from the overall result, and this number is sub-
tracted from the observed number of deaths. The resulting
quantity (O-E) will be negative if the treatment is effective,
that is the number of deaths is reduced. The standard devia-
tion of (0- E) can be calculated so that the values for
(O-E) and its variance can be summed over several trials.
The sum of (O-E) is divided by its standard deviation (the
square root of the summed variances) to test for a significant
effect in the trials as a whole.
The survival data for a two arm trial can be displayed as
shown below:
Treatment I Treatment 2
Died ri r2
Survived n,-r, n2-r2
n, n2
where r1 = no. of deaths in group 1; r2= no. of deaths in
group 2; n1 = total no. in group 1; n2= total no. in group 2.
The parameter O-E (observed - expected number of
deaths) for the treated group is calculated as follows:
0-E =(n2) (r +r2) _r2 N
The variance V, of 0- E
=nIP Q (N-n1)/(N- 1)
where N=n,+n2; P=(rI+r2)/N; Q=I-P.
The significance of (O-E) is tested by dividing it by the
square root of its variance, and referring the result to tables
of the normal distribution.
Appendix 3. Odds ratio
If the results are displayed in a table as shown in Appendix
2, the proportion in each cell can be readily calculated as
follows:786 P.M. STELL & N.S.B. RAWSON
P, = r1/N
P12 = r2/N
P21 = (n -r)IN
P22 = (n2- r2)/N
and can be displayed as follows:
Control arm 'Treated' arm
Dead pii P12
Alive P21 P22
The odds ratio, R, is then calculated as follows (Fleiss, 1981):
R = (PI, X P22)/(PI2 X P21)
The standard deviation is given as follows:
I I I I 1 \ 0-5 s.d. (logR) = + 1 + -+
VN (Pl1 P12 P21 P22
Approximate 95% confidence intervals are given as fol-
lows:
exp (logR ± 1.96 s.d. (logR))
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